NAS:TMDI (Canada)
Â
Business Description
Titan Medical Inc
NAICS : 334510
SIC : 3359
Description
Titan Medical Inc is in the research and development stage and is focused on the continued design and development of robotic-assisted surgical technologies for application in minimally invasive surgery including the development of the Enos robotic single-access surgical system.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 7.86 | |||||
| Equity-to-Asset | 0.39 | |||||
| Debt-to-Equity | 0.21 | |||||
| Debt-to-EBITDA | -0.08 | |||||
| Piotroski F-Score | 1/9 | |||||
| Altman Z-Score | -19.64 | |||||
| Beneish M-Score | -4.98 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 62.8 | |||||
| 3-Year EPS without NRI Growth Rate | 53.9 | |||||
| 3-Year FCF Growth Rate | 49.3 | |||||
| 3-Year Book Growth Rate | 15.9 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 53.33 | |||||
| 9-Day RSI | 53.43 | |||||
| 14-Day RSI | 55.1 | |||||
| 6-1 Month Momentum % | 19.31 | |||||
| 12-1 Month Momentum % | 5.02 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.41 | |||||
| Quick Ratio | 1.41 | |||||
| Cash Ratio | 1.18 | |||||
| Days Sales Outstanding | 143.37 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -72.5 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -388.65 | |||||
| Net Margin % | -213.82 | |||||
| ROE % | -97.03 | |||||
| ROA % | -60.56 | |||||
| ROIC % | -399.09 | |||||
| ROC (Joel Greenblatt) % | -1063.99 | |||||
| ROCE % | -91.51 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 9.94 | |||||
| PB Ratio | 14.59 | |||||
| Price-to-Tangible-Book | 17.51 | |||||
| EV-to-EBIT | -4.26 | |||||
| EV-to-EBITDA | -4.44 | |||||
| EV-to-Revenue | 8.88 | |||||
| EV-to-FCF | -2.77 | |||||
| Price-to-Net-Current-Asset-Value | 43.78 | |||||
| Price-to-Net-Cash | 87.55 | |||||
| Earnings Yield (Greenblatt) % | -23.47 |
